Lambda-Carrageenan Antiviral Lubricant Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current personal lubricants containing carrageenan are challenging to process into a form suitable for sexual activity due to their high viscosity and sensitivity to composition ratios, leading to drying and loss of lubricity, and there is a need for a formulation that effectively inhibits HPV transmission while maintaining performance and safety.
Innovation Solution
Development of low-viscosity antiviral lubricous compositions comprising lambda-carrageenan, processed to maintain stability and efficacy, which can be applied to skin or epithelial tissues to reduce HPV transmission and other viral infections during sexual activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If personal lubricants contain carrageenan to inhibit HPV transmission, then antiviral efficacy is improved, but viscosity increases and processing difficulty worsens
Solution Approach 1:
The patent applies parameter changes by controlling the molecular weight of lambda-carrageenan within a specific range (50,000-500,000 Da) and adjusting its concentration (0.1-5% w/v) to achieve optimal balance between antiviral efficacy and viscosity. This parameter optimization allows the lubricant to maintain HPV-inhibiting properties while ensuring processability and suitable application characteristics.
Solution Approach 2:
The patent uses composite materials by formulating lambda-carrageenan with other lubricant components including polyols (glycerol, propylene glycol), water-soluble polymers (carboxymethyl cellulose, hydroxyethyl cellulose), and buffering agents. This composite formulation combines the antiviral properties of lambda-carrageenan with the lubricating and stabilizing functions of other materials to create a balanced product that addresses both efficacy and processing requirements.
2Reliability
If carrageenan concentration is increased to enhance antiviral activity, then HPV transmission inhibition is improved, but viscosity increases and lubricity is lost
Solution Approach 1:
The patent applies parameter changes by precisely controlling the concentration of lambda-carrageenan within 0.1-5% w/v range. This optimized concentration range provides sufficient antiviral activity against HPV while maintaining appropriate viscosity and lubricity characteristics. The patent also controls molecular weight parameters to prevent excessive viscosity increase.
Solution Approach 2:
The patent applies local quality by using lambda-carrageenan specifically targeted for its antiviral function rather than general lubrication. This allows the formulation to have different functional zones: lambda-carrageenan provides localized antiviral protection at the epithelial interface, while other lubricant components provide bulk lubricity and flow properties.
3Reliability
If lambda-carrageenan is used for antiviral protection, then HPV transmission is reduced, but composition stability becomes sensitive to ratio changes
Solution Approach 1:
The patent applies parameter changes by establishing specific ranges for lambda-carrageenan molecular weight (50,000-500,000 Da) and concentration (0.1-5% w/v), along with controlling pH (6.5-7.5) and ionic strength. These parameter specifications create a stable compositional window that maintains both antiviral efficacy and formulation stability, reducing sensitivity to minor manufacturing variations.
Solution Approach 2:
The patent applies feedback by including stability-testing procedures that monitor composition consistency and antiviral activity. This quality control feedback ensures that batch-to-batch variations in lambda-carrageenan ratios or other parameters do not compromise either composition stability or HPV-inhibiting efficacy, allowing for self-correcting manufacturing processes.
Data Source
AI summary
A condom having a surface lubricated with an antiviral lubricous composition that contains carrageenan, at least one polyol selected from glycerol, propylene glycol, 1,3-propanediol, 1,3-butanediol, 1,4-butanediol, 2,3-butanediol, xylitol sorbitol, erythritol, isomalt, lactitol, maltitol, mannitol, polyethylene glycol, polypropylene glycol, one or more pH-adjusting agents that include at least one organic acid and its conjugate base, water, and, optionally, one or more of a sweetener, a preservative, a zinc salt, and a spermicide. At least 80% of the carrageenan is lambda-carrageenan, with the remainder being one or both of kappa-carrageenan and iota-carrageenan. The antiviral lubricous composition is an aqueous homogeneous solution having a turbidity less than or equal to about 25 Nephelometric Turbidity Units (NTU), a pH of from about 3.5 to about 8.0, a viscosity of from about 500 cP to about 10,000 cP, and an osmolality of from about 250 mOsmol/kg to about 1,200 mOsmol/kg.